Topiramate for the prophylaxis of episodic migraine in adults

被引:106
|
作者
Linde, Mattias [1 ]
Mulleners, Wim M. [2 ]
Chronicle, Edward P. [3 ]
McCrory, Douglas C. [4 ,5 ]
机构
[1] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway
[2] Canisius Wilhelmina Ziekenhuis, Dept Neurol, Nijmegen, Netherlands
[3] Univ Hawaii Manoa, Dept Psychol, Manoa, HI USA
[4] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[5] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA
关键词
LOW-DOSE TOPIRAMATE; DOUBLE-BLIND; PREVENTIVE TREATMENT; ANTIEPILEPTIC DRUGS; SODIUM VALPROATE; CONTROLLED-TRIAL; PLACEBO; HEADACHE; EFFICACY; IMPACT;
D O I
10.1002/14651858.CD010610
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007. Objectives To describe and assess the evidence from controlled trials on the efficacy and tolerability of topiramate for preventing migraine attacks in adult patients with episodic migraine. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2012, Issue 12), PubMed/MEDLINE (1966 to 15 January 2013), MEDLINE In-Process (current week, 15 January 2013), and EMBASE (1974 to 15 January 2013) and handsearched Headache and Cephalalgia through January 2013. Selection criteria Studies were required to be prospective, controlled trials of topiramate taken regularly to prevent the occurrence of migraine attacks, to improve migraine-related quality of life, or both. Data collection and analysis Two review authors independently selected studies and extracted data. For headache frequency data, we calculated mean differences (MDs) between topiramate and comparator (placebo, active control, or topiramate in a different dose) for individual studies and pooled these across studies. For dichotomous data on responders (patients with >= 50% reduction in headache frequency), we calculated odds ratios (ORs) and, in select cases, risk ratios (RRs); we also calculated numbers needed to treat (NNTs). We calculated MDs for selected quality of life instruments. Finally, we summarised data on adverse events from placebo-controlled trials and calculated risk differences (RDs) and numbers needed to harm (NNHs). Main results Twenty papers describing 17 unique trials met the inclusion criteria. Analysis of data from nine trials (1737 participants) showed that topiramate reduced headache frequency by about 1.2 attacks per 28 days as compared to placebo (MD -1.20; 95% confidence interval (CI) -1.59 to -0.80). Data from nine trials (1190 participants) show that topiramate approximately doubled the proportion of responders relative to placebo (RR 2.02; 95% CI 1.57 to 2.60; NNT 4; 95% CI 3 to 6). Separate analysis of different topiramate doses produced similar MDs versus placebo at 50 mg (-0.95; 95% CI -1.95 to 0.04; three studies; 520 participants), 100 mg (-1.15; 95% CI -1.58 to -0.71; six studies; 1620 participants), and 200 mg (-0.94; 95% CI -1.53 to -0.36; five studies; 804 participants). All three doses significantly increased the proportion of responders relative to placebo; ORs were as follows: for 50 mg, 2.35 (95% CI 1.60 to 3.44; three studies; 519 participants); for 100 mg, 3.49 (95% CI 2.23 to 5.45; five studies; 852 participants); and for 200 mg, 2.49 (95% CI 1.61 to 3.87; six studies; 1025 participants). All three doses also significantly improved three or more domains of quality of life as compared to placebo. Meta-analysis of the three studies that included more than one dose of topiramate suggests that 200 mg is no more effective than 100 mg. With regard to mean headache frequency and/or responder rate, seven trials using active comparators found (a) no significant difference between topiramate and amitriptyline (one study, 330 participants); (b) no significant difference between topiramate and flunarizine (one study, 83 participants); (c) no significant difference between topiramate and propranolol (two studies, 342 participants); (d) no significant difference between topiramate and relaxation (one study, 61 participants); but (e) a slight significant advantage of topiramate over valproate (two studies, 120 participants). Relaxation improved migraine-specific quality of life significantly more than topiramate. In trials of topiramate against placebo, seven adverse events (AEs) were reported by at least three studies. These were usually mild and of a non-serious nature. Except for taste disturbance and weight loss, there were no significant differences in the frequency of AEs in general, or of the seven specific AEs, between placebo and topiramate 50 mg. AEs in general and all of the specific AEs except nausea were significantly more common on topiramate 100 mg than on placebo, with NNHs varying from 3 to 25, and the RDs versus placebo were even higher for topiramate 200 mg, with NNHs varying from 2 to 17. Authors' conclusions Meta-analysis demonstrates that topiramate in a 100 mg/day dosage is effective in reducing headache frequency and reasonably well-tolerated in adult patients with episodic migraine. This provides good evidence to support its use in routine clinical management. More studies designed specifically to compare the efficacy or safety of topiramate versus other interventions with proven efficacy in the prophylaxis of migraine are needed.
引用
收藏
页数:112
相关论文
共 50 条
  • [21] Topiramate is effective for migraine prophylaxis in children
    Mack, Kenneth J.
    JOURNAL OF PEDIATRICS, 2009, 155 (03): : 447 - 448
  • [22] Topiramate for Migraine Prophylaxis in Pediatric Patients
    Deaton, Tamara L.
    Mauro, Laurie S.
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (05) : 638 - 643
  • [23] Cognitive Impairment With Topiramate in Migraine Prophylaxis
    Tyagi, Sweta
    Bala, Suman
    Badyal, Dinesh K.
    Singh, Yashpal
    INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 : S223 - S223
  • [24] Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate
    Mathew, NT
    Kailasam, J
    Meadors, L
    HEADACHE, 2002, 42 (08): : 796 - 803
  • [25] Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study
    Lipton, Richard B.
    Silberstein, Stephen
    Dodick, David
    Cady, Roger
    Freitag, Fred
    Mathew, Ninan
    Biondi, David M.
    Ascher, Steven
    Olson, William H.
    Hulihan, Joseph
    CEPHALALGIA, 2011, 31 (01) : 18 - 30
  • [26] Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine
    Mei, Daniele
    Ferraro, Diana
    Zelano, Giovanni
    Capuano, Alessandro
    Vollono, Catello
    Gabriele, Carbone
    Di Trapani, Girolamo
    CLINICAL NEUROPHARMACOLOGY, 2006, 29 (05) : 269 - 275
  • [27] Low-dose topiramate in migraine and transformed migraine prophylaxis
    Kowacs, PA
    Piovesan, EJ
    Watzko, DR
    Fameli, H
    Werneck, LC
    CEPHALALGIA, 2003, 23 (07) : 721 - 721
  • [28] Topiramate: a case series study in migraine prophylaxis
    Young, WB
    Hopkins, MM
    Shechter, AL
    Silberstein, SD
    CEPHALALGIA, 2002, 22 (08) : 659 - 663
  • [29] The Efficacy and Safety of Topiramate for Prophylaxis of Migraine in Children
    Fallah, Razieh
    Karbasi, Sedighah Akhavan
    Shajari, Ahmad
    Fromandi, Mostafa
    IRANIAN JOURNAL OF CHILD NEUROLOGY, 2013, 7 (04) : 7 - 11
  • [30] Zonisamide for Migraine Prophylaxis in Patients Refractory to Topiramate
    Emilio Bermejo, Pedro
    Dorado, Rodolfo
    CLINICAL NEUROPHARMACOLOGY, 2009, 32 (02) : 103 - 106